Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00628368|
Recruitment Status : Unknown
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : March 5, 2008
Last Update Posted : December 15, 2009
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This clinical trial is studying how well biological factors work in predicting response to treatment in patients with esophageal cancer or rectal cancer.
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer Esophageal Cancer||Genetic: gene expression analysis Genetic: mutation analysis Genetic: polymorphism analysis Other: laboratory biomarker analysis Procedure: biopsy Procedure: endoscopic biopsy||Not Applicable|
- Analyze various biological factors that can be used as markers to predict response to treatment and correlate with the signaling pathway of EGFR.
- Establish a tissue bank to store information about the response to treatment and survival.
OUTLINE: Patients undergo endoscopy, 11 biopsies of tumor tissue, and 3 biopsies of healthy mucosa. Blood samples are also collected. Samples are analyzed for the expression of 4 receptors in the EGFR family, polymorphisms at intron 1 of the EGFR gene, and gene mutations in downstream signaling pathways.
After surgery, patients are followed every 3 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||160 participants|
|Official Title:||Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of the EGFR in Response to Treatment With Neoadjuvant Chemoradiotherapy in Patients With Cancer of the Esophagus or Rectum|
|Study Start Date :||November 2005|
|Estimated Primary Completion Date :||September 2009|
- Role of predictive factors in the EGFR signaling pathway in response to treatment
- Establishment of a tissue bank
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00628368
|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle||Recruiting|
|Montpellier, France, 34298|
|Contact: Marc Ychou, MD, PhD 33-4-6761-3066 firstname.lastname@example.org|
|Study Chair:||Marc Ychou, MD, PhD||Institut du Cancer de Montpellier - Val d'Aurelle|